Becton Dickinson (BDX)

Becton Dickinson (BDX) is undergoing significant transformation as it recently spun off its life sciences business and merged with Waters Corporation (WAT), shifting focus towards becoming a pure-play medical technology company. This strategic move aims to enhance growth and profitability within higher-margin areas. However, analysts have revised earnings projections downward, forecasting $12.50 EPS for 2026 compared to the previous estimate of $15. While operating margin expectations have risen to 25%, the inherent risks associated with such structural changes warrant a cautious approach. Despite a relatively inexpensive valuation at 14x, expert opinions reflect a wait-and-see attitude, with one analyst expressing reluctance to invest in turnaround scenarios, preferring investments with more certain outcomes. The anticipated price target remains optimistic at $200.